|
1
|
Bertone-Johnson ER: Epidemiology of
ovarian cancer: A status report. Lancet. 365:101–102. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Smolle E, Taucher V and Haybaeck J:
Malignant ascites in ovarian cancer and the role of targeted
therapeutics. Anticancer Res. 34:1553–1561. 2014.PubMed/NCBI
|
|
3
|
Sun L, Li L, Li Z, Hong S, Yang Q, Qu X
and Kong B: Alterations in the serum proteome profile during the
development of ovarian cancer. Int J Oncol. 45:2495–2501. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Matsuda A and Katanoda K: Five-year
relative survival rate of ovarian cancer in the USA, Europe and
Japan. Jpn J Clin Oncol. 44:1962014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ovarian cancer, five-year stage-specific
relative survival rates (2004–2008). J Natl Cancer Inst.
103:12872011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mury D, Woelber L, Jung S, Eulenburg C,
Choschzick M, Witzel I, Schwarz J, Jaenicke F and Mahner S:
Prognostic and predictive relevance of CA-125 at primary surgery of
ovarian cancer. J Cancer Res Clin Oncol. 137:1131–1137. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Patterson DM, Gao D, Trahan DN, Johnson
BA, Ludwig A, Barbieri E, Chen Z, Diaz-Miron J, Vassilev L, Shohet
JM and Kim ES: Effect of MDM2 and vascular endothelial growth
factor inhibition on tumor angiogenesis and metastasis in
neuroblastoma. Angiogenesis. 14:255–266. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bieri M, Oroszlan M, Farkas A, Ligeti N,
Bieri J and Mohacsi P: Anti-HLA I antibodies induce VEGF production
by endothelial cells, which increases proliferation and
paracellular permeability. Int J Biochem Cell Biol. 41:2422–2430.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Qiao L, Liang N, Zhang J, Xie J, Liu F, Xu
D, Yu X and Tian Y: Advanced research on vasculogenic mimicry in
cancer. J Cell Mol Med. 19:315–326. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Awazu Y, Mizutani A, Nagase Y, Tsuchiya S,
Nakamura K, Kakoi Y, Kitahara O, Takeuchi T, Yamasaki S, Miyamoto
N, et al: Anti-angiogenic and anti-tumor effects of TAK-593, a
potent and selective inhibitor of vascular endothelial growth
factor and platelet-derived growth factor receptor tyrosine kinase.
Cancer Sci. 104:486–494. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hu P, Liu W, Wang L, Yang M and Du J: High
circulating VEGF level predicts poor overall survival in lung
cancer. J Cancer Res Clin Oncol. 139:1157–1167. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rinck-Junior JA, Oliveira C, Lourenço GJ,
Sagarra RA, Derchain SF, Segalla JG and Lima CS: Vascular
endothelial growth factor (VEGF) polymorphism and increased risk of
epithelial ovarian cancer. J Cancer Res Clin Oncol. 141:69–73.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kim KK, Singh AP, Singh RK, Demartino A,
Brard L, Vorsa N, Lange TS and Moore RG: Anti-angiogenic activity
of cranberry proanthocyanidins and cytotoxic properties in ovarian
cancer cells. Int J Oncol. 40:227–235. 2012.PubMed/NCBI
|
|
14
|
He Z, Li B, Rankin GO, Rojanasakul Y and
Chen YC: Selecting bioactive phenolic compounds as potential agents
to inhibit proliferation and VEGF expression in human ovarian
cancer cells. Oncol Lett. 9:1444–1450. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nikitina EG, Urazova LN and Stegny VN:
MicroRNAs and human cancer. Exp Oncol. 34:2–8. 2012.PubMed/NCBI
|
|
16
|
Zheng X, Dong J, Gong T, Zhang Z, Wang Y,
Li Y, Shang Y, Li K, Ren G, Feng B, et al: MicroRNA library-based
functional screening identified miR-137 as a suppresser of gastric
cancer cell proliferation. J Cancer Res Clin Oncol. 141:785–795.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Luo P, Fei J, Zhou J and Zhang W:
microRNA-126 suppresses PAK4 expression in ovarian cancer SKOV3
cells. Oncol Lett. 9:2225–2229. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kuhnert F, Mancuso MR, Hampton J,
Stankunas K, Asano T, Chen CZ and Kuo CJ: Attribution of vascular
phenotypes of the murine Egfl7 locus to the microRNA miR-126.
Development. 135:3989–3993. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang Y, Yang P, Sun T, Li D, Xu X, Rui Y,
Li C, Chong M, Ibrahim T, Mercatali L, et al: miR-126 and miR-126*
repress recruitment of mesenchymal stem cells and inflammatory
monocytes to inhibit breast cancer metastasis. Nat Cell Biol.
15:284–294. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Krek A, Grün D, Poy MN, Wolf R, Rosenberg
L, Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M,
et al: Combinatorial microRNA target predictions. Nat Genet.
37:495–500. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kozomara A and Griffiths-Jones S: miRBase:
Annotating high confidence microRNAs using deep sequencing data.
Nucleic Acids Res. 42:D68–D73. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lewis BP, Burge CB and Bartel DP:
Conserved seed pairing, often flanked by adenosines, indicates that
thousands of human genes are microRNA targets. Cell. 120:15–20.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sasahira T, Kurihara M, Bhawal UK, Ueda N,
Shimomoto T, Yamamoto K, Kirita T and Kuniyasu H: Downregulation of
miR-126 induces angiogenesis and lymphangiogenesis by activation of
VEGF-A in oral cancer. Br J Cancer. 107:700–706. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhu N, Zhang D, Xie H, Zhou Z, Chen H, Hu
T, Bai Y, Shen Y, Yuan W, Jing Q and Qin Y: Endothelial-specific
intron-derived miR-126 is down-regulated in human breast cancer and
targets both VEGFA and PIK3R2. Mol Cell Biochem. 351:157–164. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jusufović E, Rijavec M, Keser D, Korošec
P, Sodja E, Iljazović E, Radojević Z and Košnik M: Let-7b and
miR-126 are down-regulated in tumor tissue and correlate with
microvessel density and survival outcomes in non-small-cell lung
cancer. PLoS One. 7:e455772012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Musiyenko A, Bitko V and Barik S: Ectopic
expression of miR-126*, an intronic product of the vascular
endothelial EGF-like 7 gene, regulates prostein translation and
invasiveness of prostate cancer LNCaP cells. J Mol Med (Berl).
86:313–322. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Miko E, Margitai Z, Czimmerer Z, Várkonyi
I, Dezso B, Lányi A, Bacsó Z and Scholtz B: miR-126 inhibits
proliferation of small cell lung cancer cells by targeting SLC7A5.
FEBS Lett. 585:1191–1196. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Feng R, Chen X, Yu Y, Su L, Yu B, Li J,
Cai Q, Yan M, Liu B and Zhu Z: miR-126 functions as a tumour
suppressor in human gastric cancer. Cancer Lett. 298:50–63. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu L, Wang YL and Wang JF: Differential
expression of miR-21, miR-126, miR-143, miR-373 in normal cervical
tissue, cervical cancer tissue and Hela cell. Sichuan Da Xue Xue
Bao Yi Xue Ban. 43:536–539. 2012.(In Chinese). PubMed/NCBI
|
|
30
|
Frampton AE, Krell J, Jacob J, Stebbing J,
Castellano L and Jiao LR: Loss of miR-126 is crucial to pancreatic
cancer progression. Expert Rev Anticancer Ther. 12:881–884. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Herr D, Sallmann A, Bekes I, Konrad R,
Holzheu I, Kreienberg R and Wulff C: VEGF induces ascites in
ovarian cancer patients via increasing peritoneal permeability by
downregulation of Claudin 5. Gynecol Oncol. 127:210–216. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kaneko S, Ishibashi M and Kaneko M:
Vascular endothelial growth factor expression is closely related to
irinotecan-mediated inhibition of tumor growth and angiogenesis in
neuroblastoma xenografts. Cancer Sci. 99:1209–1217. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang L, Liu X, Wang H and Wang S:
Correlation of the expression of vascular endothelial growth factor
and its receptors with microvessel density in ovarian cancer. Oncol
Lett. 6:175–180. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cheng D, Liang B and Li Y: Serum vascular
endothelial growth factor (VEGF-C) as a diagnostic and prognostic
marker in patients with ovarian cancer. PLoS One. 8:e553092013.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Teng LS, Jin KT, He KF, Zhang J, Wang HH
and Cao J: Clinical applications of VEGF-trap (aflibercept) in
cancer treatment. J Chin Med Assoc. 73:449–456. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Elice F and Rodeghiero F: Side effects of
anti-angiogenic drugs. Thromb Res. Suppl 1:S50–S53. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
des Guetz G, Uzzan B, Chouahnia K and
Morere JF: Cardiovascular toxicity of anti-angiogenic drugs. Target
Oncol. 6:197–202. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang F, Ren X and Zhang X: Role of
microRNA-150 in solid tumors. Oncol Lett. 10:11–16. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Srinivasan D and Plattner R: Activation of
Abl tyrosine kinases promotes invasion of aggressive breast cancer
cells. Cancer Res. 66:5648–5655. 2006. View Article : Google Scholar : PubMed/NCBI
|
